Home > Publications database > High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. > print

001     148298
005     20240312151045.0
024 7 _ |a 10.1016/j.prp.2019.152728
|2 doi
024 7 _ |a pmid:31784096
|2 pmid
024 7 _ |a 0344-0338
|2 ISSN
024 7 _ |a 1618-0631
|2 ISSN
024 7 _ |a altmetric:71489195
|2 altmetric
037 _ _ |a DKFZ-2019-02862
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Braczynski, Anne K
|b 0
245 _ _ |a High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma.
260 _ _ |a München
|c 2020
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1710252606_32555
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Volume 216, Issue 1, January 2020, 152728
520 _ _ |a MGMT promoter methylation status is an important biomarker predicting survival and response to chemotherapy in patients suffering from glioblastoma. Since new diagnostic methods such as methylome-based classification of brain tumors are more and more frequently performed, we aimed at comparing the suitability of calculating the MGMT promoter methylation status in a quantitative manner from the methylome profiling as compared to the classic gold standard assessment by PCR.Our cohort consisted of 39 cases diagnosed as 'glioblastoma, IDH-wildtype' of which the MGMT promoter methylation status was analyzed with both methylation-specific PCR and high density DNA methylation array using the STP-27 algorithm. Contradictory results were validated by pyrosequencing.The inter-method reliability reached 77% (kappa-coefficient: 0.58) when also cases with an inconclusive result in one or the other method were taken into account. When only cases with conclusive results in both methods were considered, a very high inter-method reliability of 91% (kappa-coefficient: 0.86) could be achieved. For 'methylated' cases, no contradictory results were obtained. For the remaining two cases with discrepant results subsequent pyrosequencing analyses spoke in favor of each previously applied method once.In addition to its benefits for molecular subgrouping and copy number analysis of brain tumors, DNA-methylation based classification is a highly reliable tool for the assessment of MGMT promoter methylation status in glioblastoma patients.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Capper, David
|0 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
|b 1
|u dkfz
700 1 _ |a Jones, David T W
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 2
|u dkfz
700 1 _ |a Schittenhelm, Jens
|b 3
700 1 _ |a Stichel, Damian
|0 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17
|b 4
|u dkfz
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 5
|u dkfz
700 1 _ |a Harter, Patrick
|0 P:(DE-He78)b15b56a6ed37417d476470c60c0140ff
|b 6
700 1 _ |a Mittelbronn, Michel
|b 7
773 _ _ |a 10.1016/j.prp.2019.152728
|g p. 152728 -
|0 PERI:(DE-600)2039756-2
|n 1
|p 152728
|t Pathology, research and practice
|v 216
|y 2020
|x 0344-0338
909 C O |p VDB
|o oai:inrepo02.dkfz.de:148298
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)b15b56a6ed37417d476470c60c0140ff
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PATHOL RES PRACT : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)DD01-20160331
|k DD01
|l DKTK Koordinierungsstelle Dresden
|x 0
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pädiatrische Gliomforschung
|x 1
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 2
920 1 _ |0 I:(DE-He78)BE01-20160331
|k BE01
|l DKTK Koordinierungsstelle Berlin
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)DD01-20160331
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)BE01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21